Form 4: Arrowhead Pharmaceuticals CEO Sells Shares, Receives New Stock Grants

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold a portion of his shares to cover tax obligations and received new restricted stock units.

Summary

• Arrowhead Pharmaceuticals CEO Christopher Anzalone sold a total of 26,712 shares of common stock on December 18, 2024.
• The sales were executed in multiple transactions at weighted average prices of $20.52, $21.74, and $22.12 per share.
• These sales were made under a pre-arranged 10b5-1 trading plan.
• The sales were partially to cover tax withholding obligations related to performance-based restricted stock units (RSUs) that vested.
• The performance condition for these RSUs was certified as achieved on December 17, 2024.
• Anzalone also received 100,000 new restricted stock units on December 18, 2024, which will vest in four equal annual installments.
• Following these transactions, Anzalone's total direct holdings are 3,788,335 shares.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions. While the sale of shares could be seen as slightly negative, the grant of new RSUs balances this out. The use of a 10b5-1 plan suggests no negative implications.

Positives

• The CEO received 100,000 new restricted stock units, indicating continued alignment with the company's long-term success.
• The vesting of performance-based RSUs suggests the company met certain performance targets.

Negatives

• The CEO sold a significant number of shares, which could be perceived negatively by some investors.

Risks

• The CEO's stock sales, even if for tax purposes, could create short-term selling pressure on the stock.
• The reliance on stock-based compensation may dilute existing shareholders over time.

Industry Context

This is a routine filing related to executive stock transactions, common in the pharmaceutical industry where stock-based compensation is a significant part of executive pay.

Comparison to Industry Standards

• Executive stock sales are common across the pharmaceutical industry, often tied to vesting schedules and tax obligations.
• Companies like Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS) also use stock-based compensation for their executives, and similar Form 4 filings are regularly seen.
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, although the pre-arranged nature of the sales should mitigate concerns.
• Employees may view the vesting of performance-based RSUs positively, as it indicates the company is meeting its goals.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Christopher Anzalone, stock sale, restricted stock units, Form 4, insider trading, 10b5-1 plan, executive compensation